Press Room - Sanofi US News
WEB1 day ago · SARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Sanofi moves on J&J in first-line myeloma with FDA nod
WEB1 day ago · ASCO: With first-in-class win, Sanofi's Sarclisa looks to step out of J&J's multiple myeloma shadow. Challenging Darzalex won’t be easy. Worldwide sales of the J&J med jumped 22% and reached $9. ...
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEB11 hours ago · Third indication for Sarclisa, evaluated under FDA Priority Review, underscores Sanofi’s commitment to helping close a critical care gap in multiple myeloma (MM) PARIS, September 21, 2024 .
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa (isatuximab) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
Press Release: Sarclisa accepted for FDA priority review for ... - Sanofi
WEBMay 27, 2005 · Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma. FDA Priority Review granted based on positive results from IMROZ phase 3 study. If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care …
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer ...
WEB1 day ago · The French pharmaceutical company said Sarclisa was approved in combination with bortezomib, lenalidomide and dexamethasone. Multiple myeloma is a blood cancer that develops in plasma cells. The ...
FDA Approves Isatuximab With VRd as First-Line Option for …
WEB13 hours ago · The FDA approved isatuximab (Sarclisa; Sanofi-Aventis) with bortezomib, lenalidomide, and dexamethasone (VRd) for adults who cannot receive autologous stem cell transplant to treat their newly ...
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of ... - Sanofi
WEBDec 7, 2006 · The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy.
Sanofi wins US approval for multiple myeloma drug in newly
WEB13 hours ago · September 20, 2024 at 12:40 PM. -Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has ...
- Some results have been removed